Chonnam Med J.  2008 Dec;44(3):157-161. 10.4068/cmj.2008.44.3.157.

Therapeutic Effects of 1% Cyclosporin A Eyedrops on Herpetic Stromal Keratitis

Affiliations
  • 1Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, Korea.
  • 2Department of Pathology, Chonnam National University Medical School and Hospital, Gwangju, Korea.
  • 3Department of Ophthalmology, Ulsan Hospital, College of Medicine, Ulsan University, Ulsan, Korea.
  • 4Chonnam National University Research Institute of Medical Sciences, Gwangju, Korea. kcyoon@jnu.ac.kr

Abstract

We evaluated the therapeutic effects of topical administration of 1% cyclosporin A on herpetic stromal keratitis. Sixteen eyes of 16 patients with non-necrotizing herpetic stromal keratitis were divided into two groups according to the use of topical cyclosporin A and retrospectively reviewed. Symptom duration, visual acuity, stromal haziness, and time to improvement of stromal inflammation were analyzed. Eight eyes of 8 patients were treated with 1% cyclosporin A eyedrops in addition to conventional medication and other 8 patients (8 eyes) with conventional treatment only. There were no differences in pre-treatment symptom duration, visual acuity and stromal haziness between two groups. In cyclosporin A treatment group, visual acuity (p=0.018) and stromal haziness (p=0.034) were significantly improved after treatment. There were no differences in time to improvement of stromal inflammation (p=0.798) and post-treatment visual acuity (p=0.234) between two groups, but post-treatment stromal haziness (p=0.038) significantly improved in cyclosporin A treatment group than in conventional treatment group. Topical cyclosporin A may be effectively used in treatment of herpetic stromal keratitis for reducing stromal haziness.

Keyword

Cyclosporine; Herpes simplex keratitis; Administration, Topical
Full Text Links
  • CMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr